419 related articles for article (PubMed ID: 16373661)
1. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.
Estey E; Garcia-Manero G; Ferrajoli A; Faderl S; Verstovsek S; Jones D; Kantarjian H
Blood; 2006 May; 107(9):3469-73. PubMed ID: 16373661
[TBL] [Abstract][Full Text] [Related]
2. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.
Ravandi F; Estey E; Jones D; Faderl S; O'Brien S; Fiorentino J; Pierce S; Blamble D; Estrov Z; Wierda W; Ferrajoli A; Verstovsek S; Garcia-Manero G; Cortes J; Kantarjian H
J Clin Oncol; 2009 Feb; 27(4):504-10. PubMed ID: 19075265
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcome of acute promyelocytic leukemia treated with all-
Abaza Y; Kantarjian H; Garcia-Manero G; Estey E; Borthakur G; Jabbour E; Faderl S; O'Brien S; Wierda W; Pierce S; Brandt M; McCue D; Luthra R; Patel K; Kornblau S; Kadia T; Daver N; DiNardo C; Jain N; Verstovsek S; Ferrajoli A; Andreeff M; Konopleva M; Estrov Z; Foudray M; McCue D; Cortes J; Ravandi F
Blood; 2017 Mar; 129(10):1275-1283. PubMed ID: 28003274
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia.
Aribi A; Kantarjian HM; Estey EH; Koller CA; Thomas DA; Kornblau SM; Faderl SH; Laddie NM; Garcia-Manero G; Cortes JE
Cancer; 2007 Apr; 109(7):1355-9. PubMed ID: 17326049
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J
Hematol Oncol; 2014 Mar; 32(1):40-6. PubMed ID: 23963734
[TBL] [Abstract][Full Text] [Related]
6. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia.
Shen ZX; Shi ZZ; Fang J; Gu BW; Li JM; Zhu YM; Shi JY; Zheng PZ; Yan H; Liu YF; Chen Y; Shen Y; Wu W; Tang W; Waxman S; De Thé H; Wang ZY; Chen SJ; Chen Z
Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5328-35. PubMed ID: 15044693
[TBL] [Abstract][Full Text] [Related]
7. Role of arsenic trioxide in acute promyelocytic leukemia.
Iland HJ; Seymour JF
Curr Treat Options Oncol; 2013 Jun; 14(2):170-84. PubMed ID: 23322117
[TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
[TBL] [Abstract][Full Text] [Related]
9. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.
Platzbecker U; Avvisati G; Cicconi L; Thiede C; Paoloni F; Vignetti M; Ferrara F; Divona M; Albano F; Efficace F; Fazi P; Sborgia M; Di Bona E; Breccia M; Borlenghi E; Cairoli R; Rambaldi A; Melillo L; La Nasa G; Fiedler W; Brossart P; Hertenstein B; Salih HR; Wattad M; Lübbert M; Brandts CH; Hänel M; Röllig C; Schmitz N; Link H; Frairia C; Pogliani EM; Fozza C; D'Arco AM; Di Renzo N; Cortelezzi A; Fabbiano F; Döhner K; Ganser A; Döhner H; Amadori S; Mandelli F; Ehninger G; Schlenk RF; Lo-Coco F
J Clin Oncol; 2017 Feb; 35(6):605-612. PubMed ID: 27400939
[TBL] [Abstract][Full Text] [Related]
10. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide.
Sanford D; Lo-Coco F; Sanz MA; Di Bona E; Coutre S; Altman JK; Wetzler M; Allen SL; Ravandi F; Kantarjian H; Cortes JE
Br J Haematol; 2015 Nov; 171(4):471-7. PubMed ID: 26205361
[TBL] [Abstract][Full Text] [Related]
11. Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution.
Hu J; Shen ZX; Sun GL; Chen SJ; Wang ZY; Chen Z
Int J Hematol; 1999 Dec; 70(4):248-60. PubMed ID: 10643151
[TBL] [Abstract][Full Text] [Related]
12. The kinetics of white blood cell and the predictive factors of leukocytosis under oral or intravenous arsenic as the first-line treatment for acute promyelocytic leukemia.
Wang F; Jia JS; Wang J; Zhao T; Jiang Q; Jiang H; Zhu HH
Leuk Res; 2017 Oct; 61():84-88. PubMed ID: 28934679
[TBL] [Abstract][Full Text] [Related]
13. [Clinical observation of the short-term efficacy of the treatment with combination of all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in newly diagnosed acute promyelocytic leukemia (APL)].
Liu YF; Shen ZX; Chen X; Wang AH; Cao Q; Zhu YM; Chen SJ; Chen Z; Wang ZY
Zhonghua Xue Ye Xue Za Zhi; 2003 Jan; 24(1):25-7. PubMed ID: 12679006
[TBL] [Abstract][Full Text] [Related]
14. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation.
Leoni F; Gianfaldoni G; Annunziata M; Fanci R; Ciolli S; Nozzoli C; Ferrara F
Haematologica; 2002 May; 87(5):485-9. PubMed ID: 12010661
[TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy.
Coutre SE; Othus M; Powell B; Willman CL; Stock W; Paietta E; Levitan D; Wetzler M; Attar EC; Altman JK; Gore SD; Maher T; Kopecky KJ; Tallman MS; Larson RA; Appelbaum FR
Br J Haematol; 2014 May; 165(4):497-503. PubMed ID: 24528179
[TBL] [Abstract][Full Text] [Related]
16. Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience.
Cheng Y; Zhang L; Wu J; Lu A; Wang B; Liu G
Eur J Haematol; 2013 Dec; 91(6):483-9. PubMed ID: 24033687
[TBL] [Abstract][Full Text] [Related]
17. Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy.
Cicconi L; Breccia M; Franceschini L; Latagliata R; Molica M; Divona M; Diverio D; Rizzo M; Ottone T; Iaccarino L; Alfonso V; Foa R; Voso MT; Lo-Coco F
Ann Hematol; 2018 Oct; 97(10):1797-1802. PubMed ID: 29951912
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: a meta-analysis.
Wang H; Chen XY; Wang BS; Rong ZX; Qi H; Chen HZ
Leuk Res; 2011 Sep; 35(9):1170-7. PubMed ID: 21774985
[TBL] [Abstract][Full Text] [Related]
19. Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia.
Raffoux E; Rousselot P; Poupon J; Daniel MT; Cassinat B; Delarue R; Taksin AL; Réa D; Buzyn A; Tibi A; Lebbé G; Cimerman P; Chomienne C; Fermand JP; de Thé H; Degos L; Hermine O; Dombret H
J Clin Oncol; 2003 Jun; 21(12):2326-34. PubMed ID: 12805334
[TBL] [Abstract][Full Text] [Related]
20. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial.
Zhu HH; Wu DP; Jin J; Li JY; Ma J; Wang JX; Jiang H; Chen SJ; Huang XJ
J Clin Oncol; 2013 Nov; 31(33):4215-21. PubMed ID: 24127444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]